Levidcen

Levetiracetam, the active ingredient in Levidcen, is an antiepileptic (anticonvulsant) presented as an oral tablet for oral use. It is prescribed to control various seizure types in patients diagnosed with epilepsy, including partial‑onset, generalized tonic‑clonic and myoclonic seizures, and is used under medical supervision.

GNH USA supplies Levidcen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levetiracetam is an antiepileptic drug that reduces seizure activity in several epilepsy syndromes.

Partial‑onset seizures: reduces frequency of focal seizures and improves seizure control. Generalized tonic‑clonic seizures: helps prevent convulsive episodes in patients with generalized epilepsy. Myoclonic seizures: decreases myoclonic jerks and associated seizure burden.

Levetiracetam may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness - Somnolence - Fatigue - Irritability

Serious or Rare Side Effects: - Severe allergic reactions (anaphylaxis, Stevens‑Johnson syndrome) - Mood changes including depression or suicidal ideation - Hematologic abnormalities such as thrombocytopenia

Before initiating therapy, consider the following precautions. - Dose adjustment in renal impairment: reduce dose according to creatinine clearance. - Monitor psychiatric symptoms: watch for depression, anxiety, or suicidal thoughts. - Avoid abrupt discontinuation: taper gradually to prevent seizure worsening. - Use caution in patients with hepatic dysfunction: assess liver function before initiating. - Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Levetiracetam can interact with several medicines; awareness helps maintain efficacy and safety.

Major Interactions (Avoid): - Concomitant use with carbamazepine: may reduce levetiracetam plasma levels. - Co‑administration with enzyme‑inducing antiepileptics (e.g., phenobarbital, phenytoin): may decrease efficacy. - Strong CYP3A4 inhibitors (e.g., ketoconazole): potential increase in levetiracetam exposure.

Moderate Interactions (Monitor Closely): - Combination with other CNS depressants (e.g., benzodiazepines, alcohol): may enhance sedation. - Use with oral contraceptives: may slightly reduce contraceptive effectiveness. - Concurrent use with immunosuppressants (e.g., tacrolimus): monitor drug levels.